Advancements of antisense oligonucleotides in treatment of breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Breast cancer is a complex malignancy influenced by the overexpression of specific oncogenes, impacting patient prognosis.
• Oncogenes like HER-2, bcl-2/bcl-xL, protein kinase A (PKA), and transferrin receptor gene (TfR gene) play critical roles in breast cancer development and progression.

Purpose of the Study:

• To investigate the therapeutic potential of antisense oligonucleotides (ON) for targeting overexpressed oncogenes in breast cancer.
• To evaluate the efficacy of antisense ON as a monotherapy and in combination with conventional chemotherapy for breast cancer treatment.

Main Methods:

• Utilized antisense oligonucleotides (ON) to specifically inhibit the expression of overexpressed oncogenes at the mRNA or protein level.
• Assessed the therapeutic effects of ON in vitro on breast cancer cell lines and in vivo on xenografts.
• Investigated the synergistic effects of combining antisense ON with standard chemotherapeutic agents.

Main Results:

• Antisense ON demonstrated specific inhibition of target oncogene expression in most cases.
• Several ON candidates exhibited encouraging therapeutic effects in preclinical models of breast cancer.
• Combination therapy using antisense ON and conventional chemotherapy showed synergistic antitumor effects.

Conclusions:

• Antisense oligonucleotides represent a viable strategy for suppressing oncogene overexpression in breast cancer therapy.
• The combination of antisense ON with chemotherapy offers a potentially superior therapeutic approach for managing breast cancer.
• Antisense ON technology holds promise for improving breast cancer treatment outcomes.